Dr. Grady is a molecular biologist and board-certified gastroenterologist. He is an independent NIH funded PI with >20 years of experience in translational research related to gastrointestinal cancer. He is a Co-Head of the GI Cancer Program of the Fred Hutchinson Cancer Research Center/University of Washington Comprehensive Cancer Center and the Director of Translational Research for the Gastroenterology Division at the University of Washington. Furthermore,Dr. Grady,in his role of a practicing gastroenterologist,manages patients with a variety of gastrointestinal diseases including Barretts esophagus,colon polyps and cancer. He is the Medical Director of the GI Cancer Prevention Program Clinic at the Seattle Cancer Care Alliance,which specializes in the care of individuals who have cancer family syndromes,including Lynch syndrome and polyposis syndromes. He is one of the PIs in the Barretts Esophagus Translational Research Network (BETRNet}. He is also the PI of a multi-PI Early Detection Research Network (NCI} Biomarker Discovery Lab (co-PI S. Markowitz}. His NCI funded projects assess the role of epigenetic alterations as risk markers and biomarkers for esophageal and colon cancer,respectively. He is conducting studies that: 1} determine the role of the genetic and epigenetic alterations in the initiation and progression of colorectal and esophageal cancer; 2} determine novel treatment approaches to colorectal cancer,and 3} identify molecular factors that influence the risk for colorectal cancer.